Evolus rises on Q4 profit versus year-ago loss

Evolus

05/03/2025 15:41

** Cosmetic drugmaker Evolus' EOLS.O shares rise 1.6% to $14.58

** Evolus reported late on Tuesday Q4 adjusted income of $6.7 million, on strong sales of its cosmetic injection, compared with a year-ago loss of $3.7 million

** Expects 2025 revenue between $345 million and $355 million, compared with analysts' average expectation of $351.3 million, according to data compiled by LSEG

     ** Company projects total net revenue of at least $700 million by 2028

** Brokerage H.C. Wainwright & Co says company's tone regarding the demand in the aesthetics market was 'reassuring' given recent macro-economic uncertainty

** In the last 12 months, EOLS has fallen 2.7%

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))